Keyword: Vasant Narasimhan
Novartis and Bayer executives were among a list of attendees at a private dinner in Davos with U.S. President Donald Trump.
Just months after picking up Advanced Accelerator Applications, Novartis is getting a quick boost with the U.S. approval for Lutathera.
Incoming Novartis chief Vas Narasimhan outlined his big goals as CEO on Wednesday: Think drug launches and more drug launches.
Novartis brought on Pfizer executive—and Ibrance launch leader—Liz Barrett to head up its oncology outfit after Bruno Strigini's retirement.
Megamerger talk, executive moves real and rumored, and layoffs top FiercePharma's list of 10 best-read stories of 2017.
The FDA initially rejected Novartis' biosimilar of Amgen's Neulasta, but today the Swiss drug giant took a step forward to making a second pass.
Back in August, Novartis published findings from the phase 3 Cantos trial of Ilaris that weren't "fully compelling to payers."
Novartis investors were disappointed when CEO Joe Jimenez said that a decision about eye unit Alcon would be delayed.
Novartis has decided not to sell its $14 billion Roche stake, but that doesn't mean its strategic revamp is over.
Novartis is only in the very early days of its Kymriah rollout in the U.S., but company executives aren't only focusing on the States.